Olanib50/150mg-Olaparib

Description

Olanib50/150mg-Olaparib is a medication for Prostate and Breast cancer treatment. Olanib is a PARP inhibitor. It blocks the action of an enzyme called PARP. The brand name of this medicine is LYNPARZA.

Olaparib SPC( Summary of the Products’ Characteristics)

Olanib50/150mg-Olaparib Description:

Olaparib, a prescription medication used to treat certain types of cancer, is a PARP inhibitor. It is a PARP inhibitor, it blocks the action of an enzyme called PARP. It blocks PARP, preventing cancer cells with BRCA1 or BRCA2 mutations from repairing their DNA, leading to cell death. [1]

Olaparib indication:

• Ovarian cancer:  Olanib maintains a response to platinum-based chemotherapy in adults with recurrent ovarian cancer that has a BRCA1 or BRCA2 mutation.
• Breast cancer: Olaparib treats adults with high-risk early breast cancer that has a BRCA1 or BRCA2 mutation.
• Pancreatic cancer:  Olanib maintains a response to platinum-based chemotherapy in adults with metastatic pancreatic cancer that has a BRCA1 or BRCA2 mutation.
• Prostate cancer:  Olaparib, in combination with abiraterone and prednisone or prednisolone, treats adults with metastatic castration-resistant prostate cancer that has a BRCA1 or BRCA2 mutation. [2]

Olanib50/150mg-Olaparib Mechanism of Action:

Olaparib is a PARP inhibitor. PARP is an enzyme that helps cells repair DNA damage. Because cancer cells with certain genetic mutations, such as BRCA1 or BRCA2 mutations, rely more heavily on PARP to repair their DNA, Olanib is a particularly effective treatment for these types of cancer.

When Olaparib blocks PARP, it prevents cancer cells from repairing DNA damage. This leads to the accumulation of DNA damage, which can eventually lead to cell death.

Olaparib is most effective in cancer cells that have a BRCA1 or BRCA2 mutation. BRCA1 and BRCA2 play a role in the DNA repair pathway called homologous recombination. Homologous recombination is the most efficient way to repair double-strand DNA breaks (DSBs).

Cancer cells with a BRCA1 or BRCA2 mutation have a defect in homologous recombination. This means that they cannot repair DSBs as efficiently as normal cells. By blocking PARP, Olaparib prevents cancer cells from using the less efficient NHEJ pathway to repair DSBs.

The accumulation of DNA damage in cancer cells that are treated with Olaparib can lead to cell death. Olanib exploits synthetic lethality, which occurs when two genetic mutations interact to cause cell death. In the case of Olaparib, the BRCA1 or BRCA2 mutation and PARP inhibition are the two interacting mutations.

Olaparib has shown effectiveness in treating a variety of cancers, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It is particularly effective in treating cancers that have a BRCA1 or BRCA2 mutation. [3]

Olanib50/150mg-Olaparib Dosage and Administration:

Patients take Olanib50/150mg-Olaparib orally in tablet form, twice a day for 3 weeks out of every 4 weeks. The length of treatment depends on the type of cancer being treated and the patient’s response.

Recommended dose:

• Ovarian cancer: 300 mg twice daily (two 150 mg tablets)
• Breast cancer: 300 mg twice daily (two 150 mg tablets)
• Pancreatic cancer: 300 mg twice daily (two 150 mg tablets)
• Prostate cancer: 300 mg twice daily (two 150 mg tablets)

Dose adjustments:

If the patient experiences severe side effects, the doctor may reduce the dose of Olaparib or interrupt treatment. The doctor may also increase the dose of Olaparib if the patient is not responding to the lower dose.

Special populations:

• Patients with renal impairment: The doctor may reduce the dose of Olanib in patients with moderate or severe renal impairment.
• Patients with hepatic impairment: The doctor may reduce the dose of Olaparib in patients with severe hepatic impairment.

How to take Olanib50/150mg-Olaparib:

Swallow the Olaparib tablets whole. Do not crush, split, or chew them.

If you miss a dose of Olaparib:

If you miss a dose of Olanib, take it as soon as you remember. Otherwise, skip the missed dose and take your next dose as scheduled. Do not take two doses of Olanib at the same time.

Storage of Olaparib:

Store Olanib tablets (Olanib50/150mg) at room temperature away from moisture and heat. [4]

Olaparib Side Effects:

Olanib50/150mg-Olaparib is a medication that can cause serious side effects like nausea, vomiting, fatigue, diarrhea, decreased appetite, anemia, neutropenia, thrombocytopenia, and alopecia. Other potential side effects include infection, blood clots, liver and kidney problems, skin reactions, neurological issues, and myelodysplastic syndrome. [5]

Olanib50/150mg-Olaparib for Ovarian Cancer:

Olaparib is a PARP inhibitor that blocks the enzyme PARP, which is crucial for cancer cells with BRCA1 or BRCA2 mutations to repair DNA damage. Clinical trials have shown that Olaparib extends progression-free survival (PFS) and overall survival in patients with recurrent ovarian cancer and platinum-sensitive relapsed ovarian cancer. Patients typically take it orally twice a day for 3 weeks out of every 4 weeks. Side effects include nausea, vomiting, fatigue, diarrhea, and headache, but some may experience more serious conditions like myelodysplastic syndrome or acute myeloid leukemia. Overall, Olaparib is a safe and effective treatment for ovarian cancer. [6]

Olanib50/150mg-Olaparib for Breast Cancer:

Olaparib, an FDA-approved PARP inhibitor, blocks the PARP enzyme involved in DNA repair, killing cancer cells in adults with BRCA1 or BRCA2 mutations. Olaparib is taken orally twice a day for 3 weeks out of every 4 weeks, with treatment duration depending on the type of breast cancer and the patient’s response. Olanib is a safe and effective treatment for BRCA1 or BRCA2 mutation breast cancer, extending lives and improving quality of life.

Here are some specific examples of how olaparib has been used to treat breast cancer:

• In a clinical trial of patients with HER2-negative, BRCA1/2-mutated metastatic breast cancer, olaparib was shown to extend progression-free survival by 6 months.
• In a clinical trial of patients with early-stage, BRCA1/2-mutated breast cancer, olaparib was shown to reduce the risk of recurrence by 42%.

Olaparib is a valuable treatment option for patients with breast cancer who have BRCA1 or BRCA2 mutations. It can help to extend lives and improve quality of life.

Olanib50/150mg-Olaparib for Prostate Cancer:

Olaparib is a PARP inhibitor approved for treating certain types of prostate cancer, particularly those with BRCA1 or BRCA2 mutations. It blocks the PARP enzyme, which is involved in DNA repair, which can lead to cell death. Olaparib treats metastatic prostate cancer in men with BRCA1 or BRCA2 mutations who have already received chemotherapy and castration-resistant prostate cancer (CRPC) in men with BRCA1 or BRCA2 mutations who have progressed on other treatments. Olaparib extends progression-free survival and overall survival in patients with metastatic prostate cancer and CRPC when taken orally twice a day for 3 weeks out of every 4 weeks, depending on the type of prostate cancer and the patient’s response.

Here are some FAQs about Olanib50/150mg-Olaparib: